{"id":"NCT04429503","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","officialTitle":"A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-06-29","primaryCompletion":"2022-05-30","completion":"2024-06-18","firstPosted":"2020-06-12","resultsPosted":"2023-11-21","lastUpdate":"2025-08-08"},"enrollment":660,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema","Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"aflibercept","otherNames":["EYLEAÂ®","BAY86-5321"]},{"type":"DRUG","name":"High-dose aflibercept","otherNames":[]}],"arms":[{"label":"aflibercept Q8","type":"ACTIVE_COMPARATOR"},{"label":"High-Dose aflibercept Q12","type":"EXPERIMENTAL"},{"label":"High-Dose aflibercept Q16","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.\n\nThe secondary objectives of the study are as follows:\n\n* To determine the effect of HD vs. aflibercept on anatomic and other visual measures of response\n* To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept","primaryOutcome":{"measure":"Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48","timeFrame":"Baseline, Week 48","effectByArm":[{"arm":"Aflibercept 2 mg Every 8 Weeks (2q8)","deltaMin":8.67,"sd":0.73},{"arm":"High-dose (HD) Aflibercept Every 12 Weeks (HDq12)","deltaMin":8.1,"sd":0.61},{"arm":"HD Aflibercept Every 16 Weeks (HDq16)","deltaMin":7.23,"sd":0.71}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.0031"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":138,"countries":["United States","Canada","Czechia","Germany","Hungary","Japan","Puerto Rico","United Kingdom"]},"refs":{"pmids":["38461843"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":167},"commonTop":["Hypertension","COVID-19","Cataract Study Eye","Cataract Fellow Eye","Nasopharyngitis"]}}